Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
| ▸ | ODC1 | P11926 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205338 | 0.79 | GABRR1 (0.35) | GABRR1GLRA1SLC6A9OR51E2 | |
| SCHEMBL7389222 | 0.77 | TDP1 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL8498757 | 0.77 | TSHR (0.36) | — | |
| SCHEMBL6233401 | 0.75 | GABRR1 (0.48) | GABRR1OR51E2KDM4EALDH1A1 | |
| SCHEMBL468400 | 0.75 | ALDH1A1 (0.48) | GLRA1SLC6A9OR51E2KDM4EALDH1A1 | |
| SCHEMBL681315 | 0.72 | ALDH1A1 (0.33) | KDM4EALDH1A1 | |
| SCHEMBL10924168 | 0.72 | ODC1 (0.53) | GABRR1GLRA1SLC6A9OR51E2ODC1 | |
| SCHEMBL11097504 | 0.72 | ODC1 (0.53) | GABRR1GLRA1SLC6A9OR51E2ODC1 | |
| SCHEMBL11097500 | 0.72 | ODC1 (0.53) | GABRR1GLRA1SLC6A9OR51E2ODC1 | |
| SCHEMBL31603922 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210998-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-2314609-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2081955-B1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-8778871-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8765909-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-01 | — | — | US | disclosed |
| CN-102333520-B | Prophylactic/therapeutic agent for cancer | TAKEDA PHARMACEUTICAL | 2013-11-06 | — | — | CN | disclosed |
| EP-1577323-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8404643-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| CN-101528772-B | Metastin derivatives and uses thereof | TAKEDA PHARMACEUTICAL | 2013-03-13 | — | — | CN | disclosed |
| US-8361968-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-09 | — | — | US | disclosed |
| CN-101341168-A | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2009-01-07 | — | — | CN | disclosed |
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1963362-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007072997-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | WO | disclosed |
| EP-1758932-A2 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20060241051-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
| WO-2006001499-A2 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | WO | disclosed |
| EP-1577323-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312155-A1 | Metastin Derivatives and Use Thereof | GNRHR, SHBG, MEN1 | GABRR1 1995/4885GLRA1 4303/4885SLC6A9 3468/4885 |
| US-20060241051-A1 | Metastin derivatives and use thereof | MET, HGFAC, HGF | GABRR1 3064/4885GLRA1 4642/4885SLC6A9 3815/4885 |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | GABRR1 1552/4885GLRA1 3856/4885SLC6A9 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.